News
![Albireo Pharma: Jubiläumstipp immer höher – wann fliegt die Decke weg?](/assets/news/news17-d49b9ce9c87babddea210274f0f8d00a1cf706146ef6382020cc7ece83b76f6c.png)
Albireo Pharma: Jubiläumstipp immer höher – wann fliegt die Decke weg?
Zu unserem zehnjährigen Jubiläum stellten wir Dir Albireo Pharma (WKN: A2DF99) als Gratis-Rakete mit einem Chance-Risiko-Verhältnis vor, wie es sonst nur in unserem exklusiven No Brainer Club (NBC)
![Recordati Rare Diseases Announces First European Launch of Isturisa® (osilodrostat)](/assets/news/news16-82a218458f0e15ae617f9186b258dfd3add112716106c6ee3cbb48563ccdef52.png)
Recordati Rare Diseases Announces First European Launch of Isturisa® (osilodrostat)
Recordati Rare Diseases announced today the commercial availability of Isturisa® (osilodrostat). Over 50 patients with Cushing’s syndrome have already been initiated on Isturisa® under temporary
![Neueste NBC-Empfehlungen knallen +94% und +41% in wenigen Wochen](/assets/news/news5-af8c677c86bb4b693f58afef33877e6f798ff0d7e2b4fa69b6e89960549b5ee6.png)
Neueste NBC-Empfehlungen knallen +94% und +41% in wenigen Wochen
Kaum ist der neue Monat angebrochen, knallt es wieder in den NBC-Depots und die Cashberge der Mitglieder erreichen neue Allzeithochs: Mit MEI Pharma (WKN: A1KATX) und Pfenex (WKN: A118RA) schießen
![Aurinia Pharmaceuticals to Present at the Jefferies Virtual Healthcare Conference](/assets/news/news11-1ebbf8540812dc8f080ecfeb67ce19c492651a7c439bd800cec2630c3a04a840.png)
Aurinia Pharmaceuticals to Present at the Jefferies Virtual Healthcare Conference
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (the “Company”) today announced that Peter Greenleaf, President and Chief Executive Officer of Aurinia, will participate in a fireside chat
![Novus Therapeutics Announces Topline Results of Phase 2a Clinical Trial of OP0201 in Acute Otitis Media](/assets/news/news18-f135f6c168ef56d2b112890081403b0a310104acfadbf4a8f72634bd390e98ac.png)
Novus Therapeutics Announces Topline Results of Phase 2a Clinical Trial of OP0201 in Acute Otitis Media
Novus Therapeutics, Inc. (NASDAQ: NVUS), a specialty pharmaceutical company focused on developing products for patients with disorders of the ear, nose, and throat, today announced topline results
![Charles River Laboratories to Participate in Jefferies and William Blair Conferences](/assets/news/news7-ff65ae96e2a4b99929975e34f30f51b3393455f312fc86852d9fc8020c5054eb.png)
Charles River Laboratories to Participate in Jefferies and William Blair Conferences
Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it will virtually present at the Jefferies Virtual Healthcare Conference on Tuesday, June 2nd, at 10:00 a.m. ET, and
![Antibe Therapeutics Announces Positive Top-Line Data From Phase 2B Dose-Ranging, Efficacy Study For ATB-346](/assets/news/news3-3816cd3656012f9a06bae00ff06108b383643da017a8247fff474f84ea8a7c5a.png)
Antibe Therapeutics Announces Positive Top-Line Data From Phase 2B Dose-Ranging, Efficacy Study For ATB-346
- ATB-346 demonstrates superiority to placebo in reducing osteoarthritis pain -
- ATB-346 is more potent than expected; lowest effective dose still to be established -
- Antibe plans
![Pfizer Provides Update on Phase 3 PALLAS Trial of IBRANCE® (palbociclib) Plus Endocrine Therapy in HR+, HER2- Early Breast Cancer](/assets/news/news15-207f60e93f55a63563671c62b1e07d0bc426e50a03c286a608f29c8138f4f1de.png)
Pfizer Provides Update on Phase 3 PALLAS Trial of IBRANCE® (palbociclib) Plus Endocrine Therapy in HR+, HER2- Early Breast Cancer
As announced today by the Austrian Breast & Colorectal Cancer Study Group and the Alliance Foundation Trials, LLC, Pfizer Inc. (NYSE: PFE) reports that following a preplanned efficacy and futility
![Nanobiotix Announces Positive First Results From Phase I Expansion in Locally Advanced Head and Neck Cancer at ASCO 2020](/assets/news/news19-14feaf1b3ac689101974b5354f2ab8bb5cb2e7cb49a06b120b8491e9ebba31f4.png)
Nanobiotix Announces Positive First Results From Phase I Expansion in Locally Advanced Head and Neck Cancer at ASCO 2020
Regulatory News:
NANOBIOTIX (Paris:NANO)(Euronext: NANO - ISIN: FR0011341205 – the “Company”), a clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, today
![Sangamo Therapeutics Announces Participation at the Jefferies Virtual Healthcare Conference](/assets/news/news11-1ebbf8540812dc8f080ecfeb67ce19c492651a7c439bd800cec2630c3a04a840.png)
Sangamo Therapeutics Announces Participation at the Jefferies Virtual Healthcare Conference
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that management will present at the Jefferies Virtual Healthcare Conference on Tuesday, June 2 at 4:00 p.m
![Clinical Response and Translational Data from DeCidE1, a Phase 2 Study of DPX-Survivac Immunotherapy in Patients with Advanced Recurrent Ovarian Cancer](/assets/news/news13-125fa69a38b6955d740c18f7e750c42a3317f6873eded3044187d2ece3aa0ac7.png)
Clinical Response and Translational Data from DeCidE1, a Phase 2 Study of DPX-Survivac Immunotherapy in Patients with Advanced Recurrent Ovarian Cancer
IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical-stage biopharmaceutical company pioneering a novel class of targeted cancer immunotherapies and vaccines against infectious diseases, today reported
![Paion, Evotec, Aurora Cannabis: 3 Perlen für 2020?](/assets/news/news1-f26f2455ece0c3cbea64441818e795358cadddddb27e796f883ae2bd06f66139.png)
Paion, Evotec, Aurora Cannabis: 3 Perlen für 2020?
Paion (WKN: A0B65S) nähert sich der wegweisenden Marktzulassung seines Anästhetikums in den USA. Die Entscheidung fällt am 5. Juli. Die überwiegend wahrscheinliche Zulassung würde für das
![QIAGEN Builds on Leading Position in Precision Medicine With Novel Solutions in Oncology](/assets/news/news12-a6c8e663da6f66e4f8b76885d84b91bc276bfd92fd8727e9ade1f1d9f4df9b67.png)
QIAGEN Builds on Leading Position in Precision Medicine With Novel Solutions in Oncology
QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the launch of novel solutions enabling faster, better analysis of genomic variations in cancer – accelerating multiple
![Clovis Oncology Announces New Recommendations for Rubraca® (rucaparib) Tablets in Updated National Comprehensive Cancer Network (NCCN) Guidelines® for the Treatment of Metastatic Castration-Resistant Prostate Cancer (mCRPC)](/assets/news/news15-207f60e93f55a63563671c62b1e07d0bc426e50a03c286a608f29c8138f4f1de.png)
Clovis Oncology Announces New Recommendations for Rubraca® (rucaparib) Tablets in Updated National Comprehensive Cancer Network (NCCN) Guidelines® for the Treatment of Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Clovis Oncology, Inc. (NASDAQ: CLVS), announced today that the National Comprehensive Cancer Network® (NCCN) updated its Clinical Practice Guidelines in Oncology for Prostate Cancer to include new
![Savara to Present at the Jefferies Virtual Healthcare Conference](/assets/news/news8-29d1d55c755b03e328399113b5bdd004223f995e95194ba5ee80af9da39a41e3.png)
Savara to Present at the Jefferies Virtual Healthcare Conference
Savara Inc. (Nasdaq: SVRA), an orphan lung disease company, today announced that Savara management will be presenting at the Jefferies Virtual Healthcare Conference on Wednesday, June 3, 2020 at
![Transgene: Combined General Meeting of May 27, 2020](/assets/news/news7-ff65ae96e2a4b99929975e34f30f51b3393455f312fc86852d9fc8020c5054eb.png)
Transgene: Combined General Meeting of May 27, 2020
Regulatory News:
The Combined Ordinary and Extraordinary General Meeting of Transgene’s (Paris:TNG) shareholders was held today (May 27, 2020) at 10:00 a.m. at the Company's headquarters (400
![ICON plc to Present at Jefferies Virtual Healthcare Conference](/assets/news/news17-d49b9ce9c87babddea210274f0f8d00a1cf706146ef6382020cc7ece83b76f6c.png)
ICON plc to Present at Jefferies Virtual Healthcare Conference
ICON plc, (NASDAQ: ICLR) a global provider of drug and device development and commercialisation services to the pharmaceutical, biotechnology and medical device industries, today announced that Dr
![Xencor to Present at Upcoming Investor Conferences](/assets/news/news7-ff65ae96e2a4b99929975e34f30f51b3393455f312fc86852d9fc8020c5054eb.png)
Xencor to Present at Upcoming Investor Conferences
Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer and autoimmune diseases, today announced that Bassil
![Aurinia Completes Submission of New Drug Application to the U.S. Food & Drug Administration for Voclosporin for the Treatment of Lupus Nephritis](/assets/news/news4-fce0efe65d8ba787508ef718c0a20bed51e468dbc656c188c43e13f15b4a4f53.png)
Aurinia Completes Submission of New Drug Application to the U.S. Food & Drug Administration for Voclosporin for the Treatment of Lupus Nephritis
Aurinia Pharmaceuticals Inc. (Nasdaq:AUPH / TSX:AUP) (“Aurinia” or the “Company”), a late-stage clinical biopharmaceutical company focused on advancing voclosporin across multiple indications
![Pfizer Inc. Recommends Rejection of Unsolicited Note Tender Offer by Huguenot Bond Liquidity, LLC](/assets/news/news9-b4ba75b613b80e3d047ded18f34335e7f81348578b67aee3f1469440916c031e.png)
Pfizer Inc. Recommends Rejection of Unsolicited Note Tender Offer by Huguenot Bond Liquidity, LLC
Pfizer Inc. (NYSE: PFE) today announced that it and Wyeth recommend rejection of the unsolicited tender offer made by Huguenot Bond Liquidity, LLC (“Offeror”) on May 11, 2020 (as amended and
![Navidea Biopharmaceuticals Announces Positive Results of Second Interim Analysis of Ongoing Phase 2B Study in Rheumatoid Arthritis](/assets/news/news14-e52b56a6adda780de8ab40d75cabe14dcfa77fc9676e986401297a29e68c991e.png)
Navidea Biopharmaceuticals Announces Positive Results of Second Interim Analysis of Ongoing Phase 2B Study in Rheumatoid Arthritis
Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, is pleased to
![Clovis Oncology Announces Presentations at 2020 ASCO Virtual Scientific Program](/assets/news/news1-f26f2455ece0c3cbea64441818e795358cadddddb27e796f883ae2bd06f66139.png)
Clovis Oncology Announces Presentations at 2020 ASCO Virtual Scientific Program
Clovis Oncology, Inc. (NASDAQ: CLVS), announced today that six abstracts featuring data from clinical and real-world evidence studies evaluating Rubraca® (rucaparib) in multiple tumor types have
![IMV Announces Selection of a Vaccine Candidate Against COVID-19 to Advance Into Human Clinical Studies](/assets/news/news9-b4ba75b613b80e3d047ded18f34335e7f81348578b67aee3f1469440916c031e.png)
IMV Announces Selection of a Vaccine Candidate Against COVID-19 to Advance Into Human Clinical Studies
IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical-stage biopharmaceutical company pioneering a novel class of cancer immunotherapies and vaccines against infectious diseases, today announced positive
![Sensorion Publishes Results of General Assembly Resolutions](/assets/news/news1-f26f2455ece0c3cbea64441818e795358cadddddb27e796f883ae2bd06f66139.png)
Sensorion Publishes Results of General Assembly Resolutions
Regulatory News:
Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotech company which specializes in the development of novel therapies to restore, treat and prevent within the
![NEOVACS SHARES TO RESUME TRADING ON MAY 20TH, 2020](/assets/news/news12-a6c8e663da6f66e4f8b76885d84b91bc276bfd92fd8727e9ade1f1d9f4df9b67.png)
NEOVACS SHARES TO RESUME TRADING ON MAY 20TH, 2020
Paris and Boston, May 19th, 2020 5:30 PM CET - Néovacs (Euronext Growth Paris: ALNEV) confirms that it has requested the resumption of trading in its shares on Euronext as soon as possible in